Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

EVALUATING THE MIDTERM SAFETY AND EFFICACY OF A HYDROXYAPATITE-COATED FEMORAL STEM: INTERIM RESULTS FROM A PROSPECTIVE, MULTICENTRE, OBSERVATIONAL STUDY

International Society for Technology in Arthroplasty (ISTA) meeting, 32nd Annual Congress, Toronto, Canada, October 2019. Part 2 of 2.



Abstract

INTRODUCTION

Cementless femoral component designs supplemented with hydroxyapatite (HA) coating have been hypothesised to enhance osseointegration, thereby improving stability and clinical outcomes. We herein offer interim results at 5 years from a prospective, multi-centre study of a femoral stem (SL-PLUS™ Hip Stem Prosthesis), forged from titanium alloy (Ti6Al7Nb) and consisting of a titanium plasma sprayed coating (0.3mm) with an additional 0.05mm layer of HA.

METHODS

Investigators at 2 centres enrolled patients between 18–75 years of age who underwent primary total hip arthroplasty (THA) with this HA-coated stem. The study's primary outcome was the clinical efficacy of the stem, as measured by the Harris Hip Score (HHS), Western Ontario & McMaster Universities Osteoarthritis (WOMAC) Score calculated out of Hip Disability and Osteoarthritis Outcome Score (HOOS), and the EuroQol EQ-5D-3L index score and visual analogue scale (VAS). Its secondary outcomes included a radiographic assessment of implant position and fixation, and overall safety, as measured by intraoperative/early postoperative complications and survivorship calculated using Kaplan-Meier estimates.

RESULTS

Ninety-three patients (94 hips) were enrolled in the study. At the time of surgery, the study population had a mean age of 60.1 years (standard deviation [SD], 8.4), a mean body mass index of 27.9 kg/m2 (SD, 4.75), and 54.8% were female. Indications for surgery include primary osteoarthritis (74.5%), dysplasia (17.5%), femoral head necrosis (6.4%), and other (2.1%). Patients were followed up through 5 years in the ongoing safety and performance analysis. Between preoperative baseline and final follow up, there were notable improvements in the mean scores for all primary clinical outcomes: HHS (51.6 to 91.4, respectively), WOMAC from HOOS (42.6 to 91.0, respectively), mean EQ-5D-3L index score (0.7 to 0.9, respectively), and EQ-5D-3L VAS (54.7 to 80.2, respectively). The majority of patients rated their satisfaction as excellent (84.2% of treated hips), with an additional 14.5% of treated hips being mostly satisfied. Five years after surgery, radiographic findings showed an overall stability of the device, with 100% unchanged stem positions (no movement in varus/valgus or subsidence) and no stem was classified as loose. Intraoperative complications were observed in 3 patients (3.2%), consisting of 2 cases of trochanteric fracture and 1 case of leg lengthening. There were no general early postoperative complications reported in any patient. Two revision surgeries of the study device were reported, both due to infection, resulting in a survivorship of 97.5% (95% confidence interval: 90.3% – 99.4%) at 5 years.

CONCLUSION

These results confirm the safety and efficacy of this HA-coated femoral stem at 5 years. All clinical outcomes showed significant improvement between baseline and midterm follow up, with mean HHS in particular meeting the 90-point range considered “excellent.” Additionally, revision rates met the accepted benchmarks for a successful THA device.

For any figures or tables, please contact authors directly.